Share on StockTwits

Cytosorbents Corp (NASDAQ:CTSO) Director Al Kraus sold 100,000 shares of the stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $0.25, for a total value of $25,000.00. Following the completion of the sale, the director now directly owns 1,393,631 shares of the company’s stock, valued at approximately $348,408. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Cytosorbents Corp (NASDAQ:CTSO) traded down 2.08% during mid-day trading on Thursday, hitting $0.235. The stock had a trading volume of 713,624 shares. Cytosorbents Corp has a 52 week low of $0.09 and a 52 week high of $0.35. The stock has a 50-day moving average of $0.25 and a 200-day moving average of $0.24. The company’s market cap is $73.0 million.

Cytosorbents Corp (NASDAQ:CTSO) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.01) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.01). On average, analysts predict that Cytosorbents Corp will post $-0.03 earnings per share for the current fiscal year.

Separately, analysts at HC Wainwright initiated coverage on shares of Cytosorbents Corp in a research note on Monday, August 18th. They set a “buy” rating and a $1.00 price target on the stock.

CytoSorbents Corporation is a development stage critical care focused company using blood purification to treat life-threatening illnesses.

Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.